MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed)

0
201

Funding Opportunity ID: 323573
Opportunity Number: RFA-RM-20-009
Opportunity Title: MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.310
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Jan 10, 2020
Close Date: Mar 20, 2020
Last Updated Date: Jan 10, 2020
Award Ceiling: $0
Award Floor: $0
Estimated Total Program Funding:
Expected Number of Awards:
Description: The purpose of this FOA is to invite additional applications for the Preclinical Animal Study Sites (PASS) as part of the Molecular Transducers of Physical Activity in Humans Consortium (MoTrPAC) (http://commonfund.nih.gov/MolecularTransducers). Awards made through this FOA will support preclinical mechanistic studies on a range of molecular compounds identified in the initial PASS exercise protocol (RM 15-013) which was designed to complement and substantially expand the data from the human clinical study. This FOA is expected to support up to 4-6 additional PASS as part of the MoTrPAC consortium. Phase 2 of the original PASS study sites will design and conduct detailed mechanistic studies to identify the sources, signaling pathways, physiological targets, and functions of mobilized and identified molecular transducers of physical activity; to recognize feedback and interaction effects among different pathways and tissues; and to discover specific roles of the molecules associated with specific health benefits. This RFA calls for additional proposals to explore the mechanistic links between the candidate molecular transducers of physical activity and functional effects of exercise in tissues. Overall, data from the PASS studies are anticipated to substantially increase our understanding of how different tissues and organs adapt to the exercise induced changes. The PASS will serve to confirm human data and extend the analyses of candidate transducers of physical activity from the clinical study across multiple organs and tissues that are not accessible from human participants. Applicants should propose what they think is the best strategy and approach for investigating how these mobilized compounds synergize to coordinate the overall homeostatic response to exercise. Final decisions on the actual compounds for future screening will be determined in consultation with the MoTrPAC Steering Committee.
Version: 1





Visit the Official Webpage For More Details on MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here